Butterfly on yellow flowers for EicOsis home page

Developing a New Approach to Treat Pain

At EicOsis, we are addressing the opioid crisis by developing a novel, safe and effective oral treatment for people and animals suffering from pain.

Discover More

Pain Management

Understand the unmet needs of those suffering from pain and how EicOsis is working to make a difference in pain management.

Our Approach

Learn how our novel technology, targeting the soluble Epoxide Hydrolase, can help us develop new safe and effective oral analgesics.

Media & Investors

Interested in learning more about our work and accomplishments? Spread the news on EicOsis’s progresses and be part of them!

Hands clasping after treatment for pain

Latest News: EicOsis Started Human Clinical Trials in 2019

EicOsis started Phase 1 human clinical trials in 2019 after obtaining IND clearance from the US FDA. Our goal is to develop an oral drug to alleviate pain, creating a viable option for a safer, non-addictive, effective analgesic.

Learn More

Targeting a New Pathway to Address the Unmet Needs of Pain Patients and Fight the Opioid Crisis

 

Chronic pain affects 100 million Americans and causes a substantial physical and emotional impact on their lives. Current treatments for pain are insufficient, and patients are often prescribed opioids. Increased prescription of opioids has led to a widespread public health emergency, the US Opioid Crisis. There is an unmet need for safe, non-addictive and effective pain medications that can help pain patients and fight the US Opioid Crisis.

At EicOsis we are developing a new approach to treat pain by inhibiting the soluble Epoxide Hydrolase (sEH), a key regulatory enzyme. Inhibiting sEH increases the levels of naturally occurring anti-inflammatory and pain-relieving compounds. Our first drug candidate is currently undergoing Phase 1 human clinical trials. Learn more about EicOsis Human Health.

EicOsis Has Been Awarded over 20 Million in Competitive Grants and Funding

EicOsis is advancing its first drug candidate to human clinical trials with the support of funding from federal grants and angel investors.

October, 2019 – EicOsis receives SBIR grant award from NCI/NIH

October, 2019 – EicOsis receives $15 M from NIDA/NIH as part of the HEAL Initiative

March, 2019 – EicOsis raises funding for Phase 1 clinical development from Open Philanthropy

January, 2019 – EicOsis receives $4 M from NIH Blueprint for Neuroscience Research to advance oral analgesic to Phase 1 clinical trials for neuropathic pain

Learn more about our funding sources.